Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

88.88
+3.634.26%
Post-market: 88.80-0.0800-0.09%19:45 EDT
Volume:857.13K
Turnover:75.65M
Market Cap:22.31B
PE:-16.10
High:89.54
Open:86.29
Low:86.29
Close:85.25
52wk High:124.00
52wk Low:79.52
Shares:251.00M
Float Shares:105.00M
Volume Ratio:1.15
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5189
EPS(LYR):-5.5184
ROE:-5.88%
ROA:-3.56%
PB:1.00
PE(LYR):-16.11

Loading ...

Biontech Closes Acquisition Of CureVac

Reuters
·
Dec 18, 2025

BioNTech Closes Acquisition of CureVac

Reuters
·
Dec 18, 2025

Andon Health Gets US Approval for Flu, COVID-19, RSV Test Kits

MT Newswires Live
·
Dec 15, 2025

Berenberg Raises Price Target on BioNTech to $155 From $150, Keeps Buy Rating

MT Newswires Live
·
Dec 11, 2025

U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, Synopsys

Reuters
·
Dec 11, 2025

BioNTech Se : Berenberg Raises Target Price to $155 From $150

THOMSON REUTERS
·
Dec 11, 2025

Debate On Vaccine Safety Reaches Policy Stage - FDA Broadens Review Into Covid-19 Shot Risks In Adults

Benzinga
·
Dec 10, 2025

Biontech, Bristol Myers Squibb Present Global Phase 2 Data For Pumitamig

Reuters
·
Dec 09, 2025

BioNTech and Bristol Myers Squibb Report Positive Phase 2 Results for Pumitamig in Advanced Triple-Negative Breast Cancer

Reuters
·
Dec 09, 2025

European Equities Traded in the US as ADRs Little Changed in Monday Trading

MT Newswires Live
·
Dec 09, 2025

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires Live
·
Dec 08, 2025

BioNTech, OncoC4 Say Lung Cancer Phase 3 Trial Shows 'Meaningful' Overall Survival Benefit; Shares Up Pre-Bell

MT Newswires Live
·
Dec 08, 2025

Stock Track | BioNTech SE Soars 6.22% on Positive Clinical Trial Results for Lung Cancer Drug

Stock Track
·
Dec 08, 2025

Biontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug

Reuters
·
Dec 08, 2025

BioNTech Reports Gotistobart Shows Significant Survival Benefit in Phase 3 Lung Cancer Trial

Reuters
·
Dec 07, 2025

BioNTech Secures 81.7% of CureVac Shares in Tender Offer

Reuters
·
Dec 03, 2025

BioNTech SE ADR Sheds 5.6%, Underperforms Market

Dow Jones
·
Dec 02, 2025

Stock Track | BioNTech SE Plummets 5.02% Intraday Amid FDA Stricter Vaccine Approval Rules

Stock Track
·
Dec 02, 2025

Stock Track | BioNTech SE Plummets 5.02% Intraday as FDA Tightens Vaccine Approval Rules

Stock Track
·
Dec 02, 2025

Stock Track | BioNTech SE Plummets 5.02% as FDA Proposes Stricter Vaccine Approval Rules

Stock Track
·
Dec 02, 2025